An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2018
At a glance
- Drugs CYAD 01 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms DEPLETHINK
- Sponsors Celyad
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Planned End Date changed from 3 Aug 2034 to 1 Aug 2021.
- 05 Jun 2018 Planned primary completion date changed from 3 Aug 2021 to 1 Aug 2021.